Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine

Pharmacopsychiatry

Volumn 44, Issue 4, 2011, Pages 142-147

  Molina, J D ^a,f   Toledo Romero, F ^b   Lopez Rodriguez E ^c   Amorin Diaz M ^d   Lerma Carrillo, I ^a   Lopez Munoz F ^e,f  

^a Hospital Dr Rodríguez Lafora   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL RAFAEL MÉNDEZ   (Spain)

^d Northwest District Hospital Caravaca   (Spain)

^e UNIVERSITY OF ALCALÁ   (Spain)

^f CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

amisulpride; augmentation; olanzapine; schizophrenia; treatment resistance

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; BIPERIDEN; FLUPHENAZINE; HALOPERIDOL; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ABSENTEEISM; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LIBIDO DISORDER; MALE; MENTAL HEALTH; MONOTHERAPY; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UDVALG FOR KLINISKE UNDERSOGELSER SIDE EFFECT RATING SCALE; WEIGHT GAIN;

EID: 79959481588     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1279728     Document Type: Article

References (49)

1. Heresco-Levy U, Greenberg D, Wittman L et al,. Prescribing patterns of neuroactive drugs in 98 schizophrenic patients. Isr J Psychiatry Relat Sci 1989 26 157-163 (Pubitemid 20061470)
2. Kiivet RA, Llerena A, Dahl ML et al,. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995 40 467-476
3. Ungvari GS, Pang AH, Chiu HF et al,. Psychotropic drug prescription in rehabilitation. A survey in Hong Kong. Soc Psychiatry Psychiatr Epidemiol 1996 31 288-291 (Pubitemid 26340968)
4. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999 53 Suppl S35-S40
5. Rittmannsberger H, Meise U, Schauflinger K et al,. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999 14 33-40
6. Wang PS, West JC, Tanielian T et al,. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000 26 451-457 (Pubitemid 30423221)
7. Fourrier A, Gasquet I, Allicar MP et al,. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000 49 80-86 (Pubitemid 30050490)
8. Procyshyn RM, Kennedy NB, Tse G et al,. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001 46 334-339 (Pubitemid 32531565)
9. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration New York metropolitan region. Schizophr Bull 2002 28 31-42 (Pubitemid 34534748)
10. Covell NH, Jackson CT, Evans AC et al,. Antipsychotic prescribing practices in Connecticutâs public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002 28 17-29 (Pubitemid 34534747)
11. Clark RE, Bartels SJ, Mellman TA et al,. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002 28 75-84 (Pubitemid 34534751)
12. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003 64 984-989 (Pubitemid 37158242)
13. Flórez Menéndez G, Blanco Ramos M, Gómez-Reino Rodríguez I et al,. Polypharmacy in the antipsychotic prescribing practices in psychiatric out-patient clinic. Actas Esp Psiquiatr 2004 32 333-339 (Pubitemid 39643678)
14. Ganguly R, Kotzan JA, Miller LS et al,. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 19982000. J Clin Psychiatry 2004 65 1377-1388
15. Sim K, Su A, Fujii S et al,. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004 58 178-183 (Pubitemid 39043998)
16. Janssen B, Weinmann S, Berger M et al,. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004 30 1023-1033 (Pubitemid 40469534)
17. Faries D, Ascher-Svanum H, Zhu B et al,. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005 5 26
18. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists perceptions of antipsychotic drug prescription. Br J Psychiatry 2005 187 243-247 (Pubitemid 41306105)
19. Ghaemi SN. Polypharmacy in psychiatry. New York Marcel Dekker 2002
20. Kane JM, Leucht S, Carpenter D et al,. Treatment of schizophrenia 1999. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003 64 Suppl. 12 5-19
21. Lehman AF, Lieberman JA, Dixon LB et al,. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 161 Suppl. 2 1-56
22. Miller AL, Crismon ML, Rush AJ et al,. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 2004 30 627-647 (Pubitemid 39625707)
23. Lehman AF, Kreyenbuhl J, Buchanan RW et al,. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004 30 193-217 (Pubitemid 38828528)
24. National Institute for Mental Health in England. Implementing NICE Guidance. Available at http://www.schizophreniaguidelines.co.uk/
25. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in psychiatry. Current Op Psych 2010 23 103-111
26. Wang J, Omori IM, Fenton M et al,. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010 Jan 20 1 CD008125
27. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009 Jul 8 3 CD006324
28. Tylor DM, Smith L. Augmentation of clozapine with a second antipsycchotic. A meta-analysis of randomized, placebo controlled studies. Acta psychiatr Scand 2009 119 419-425
29. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007 27 198-204 (Pubitemid 46594939)
30. National Association of State Mental Health Program Directors, Medical Directors Council and State Medicaid Directors. NASMHPD Medical Directors Technical Report on Psychiatric Polypharmacy. Alexandria NASMHPD Research Institute, Inc. 2001
31. Lerma-Carrillo I, de Pablo Brühlmann S, del Pozo ML et al,. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 2008 31 319-332
32. Molina JD, Lerma-Carrillo I, Leonor M et al,. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a one-year retrospective study. Clin Neuropharmacol 2009 32 10-15
33. Lerma-Carrillo I, Molina JD, Gonzalez-Parra S et al,. Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2008 15 e420-e421
34. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2004 7 Suppl. 1 S15-S20 (Pubitemid 38436992)
35. Kissling W. Compliance, quality management and standards in the treatment of schizophrenia. Neuropsychobiology 1997 35 70-72 (Pubitemid 27117215)
36. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004 19 56-58 (Pubitemid 38210430)
37. Zink M. Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatr Neurosci 2005 30 409-415 (Pubitemid 41812487)
38. Zink M. Optimizing the antipsychotic potency of olanzapine by augmentation- a critical review. Psychiatr Prax 2006 33 261-268 (Pubitemid 44369579)
39. Pedrosa Gil F, Schneider C, Grohmann R. Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy. Nervenartz 2001 72 729-733 (Pubitemid 32852332)
40. Munro J, Matthiasson P, Osborne S et al,. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004 110 292-298 (Pubitemid 39278988)
41. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962 10 799-812
42. Guy W. ECDEU Assessment Manual for Psychopharmacology Revised (DHEW Publ No ADM 76-338). Rockville Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976 218-222
43. Lingjaerde O, Ahlfors UG, Bech P et al,. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987 76 1-100 (Pubitemid 17115352)
44. Tapp A, Wood AE, Secrest L et al,. Combination antipsychotic therapy in clinical practice. Psychiatric Serv 2003 54 55-59 (Pubitemid 36043847)
45. Correll CU, Rummel-Kluge C, Cirves C et al,. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009 35 443-457
46. Correll CU, Malhotra AK, Kaushik S et al,. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003 160 2063-2065 Erratum in: Am J Psychiatry 2005; 162: 1774 (Pubitemid 39619650)
47. Leucht S, Bush R, Kissling W et al,. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007 68 352-360 (Pubitemid 46506798)
48. Lieberman JA, Stroup S, McEvoy JP et al,. Effectiveness of antipsychotic drugs in patients with chronic schizophrrenia. N Engl J Med 2005 353 1209-1223 (Pubitemid 41345943)
49. Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008 8 1-14